1-Methyltryptophan

changed 477208146 1-methyltryptophan.svg skin-invert-image 200px 1-Methyltryptophan 2-Amino-3-(1-methyl-1H-indol-3-yl)propanoic acid 1-Methyl-DL-tryptophan; DL-1-Methyltryptophan; ARBRIN; Indoximod 4694 26988-72-7 (D/L) changed ?? 21339-55-9 (L) correct CAS 98112 changed EBI 504816 correct EBI 514172 correct chemspider 1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16) correct chemspider ZADWXFSZEAPBJS-UHFFFAOYSA-N 88584 correct chemspider O=C(O)C(N)Cc2c1ccccc1n(c2)C InChI=1S/C12H14N2O2/c1-14-7-8(6-10(13)12(15)16)9-4-2-3-5-11(9)14/h2-5,7,10H,6,13H2,1H3,(H,15,16) ZADWXFSZEAPBJS-UHFFFAOYSA-N 12 14 2 2 1-Methyltryptophan is a chemical compound that is an inhibitor of the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO or INDO 1.13.11.52). Cady SG Sono M 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-3-benzo[b]thienyl-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase Archives of Biochemistry and Biophysics 291 2 326–33 1991 1952947 10.1016/0003-9861(91)90142-6 It is a chiral compound that can exist as both D- and L-enantiomers. The L-isomer (L-1MT) inhibits IDO weakly but also serves as an enzyme substrate. The D-isomer (D-1MT) does not inhibit IDO at all, but it can inhibit the IDO-related enzyme IDO2 17671174 2007 Metz R Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan Cancer Research 67 15 7082–7 Duhadaway J. B. Kamasani U Laury-Kleintop L Muller A. J. Prendergast G. C. 10.1158/0008-5472.CAN-07-1872 free and restore mTOR signaling in cells starved of tryptophan due to IDO activity. 23264892 3525601 2012 Metz R IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan OncoImmunology 1 9 1460–1468 Rust S Duhadaway J. B. Mautino M. R. Munn D. H. Vahanian N. N. Link C. J. Prendergast G. C. 10.4161/onci.21716 D-1MT is also known as indoximod and it was in clinical trials for cancer treatment, such as for advanced melanoma, in 2017.IDO Inhibitors Emerging as New Players on Checkpoint Blockade Scene. Aug 2017January 2025 A U.S. patent covering salt and prodrug formulations of indoximod was issued to NewLink Genetics on August 15, 2017, providing exclusivity until at least 2036.https://finpedia.co/bin/Companies/NewLink%20Genetics%20Corp/ NewLink Genetics finpedia.co 2019-05-09June 2026 InternetArchiveBot https://fintel.io/doc/sec-nlnk-newlink-genetics-10ka-2018-april-09-17956 NewLink Genetics Annual Report (Form 10-K) fintel.io April 9, 2018 References Category:1-Alkyltryptamines Category:Alpha-amino acids Category:Oxidoreductase inhibitors